{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/tamoxifen-managing-adverse-effects/","result":{"data":{"firstChapter":{"id":"68b30489-1c21-5691-aa91-d98c85819055","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field a8b67e55-9f08-48b4-959d-19bebc53d33e --><h1>Tamoxifen - managing adverse effects: Summary</h1><!-- end field a8b67e55-9f08-48b4-959d-19bebc53d33e -->","htmlStringContent":"<!-- begin item 0845f642-9890-4944-91cd-c221e12362a5 --><!-- begin field 88227c79-471e-44f4-8daf-0522c2290da6 --><ul><li>Tamoxifen is a selective oestrogen receptor modulator (SERM).<ul><li>SERMs are nonsteroidal, triphenylethylene-based drugs that bind to oestrogen receptors, resulting in oestrogen agonist or oestrogen antagonist-like effects of varying magnitudes in different tissues. </li><li>In the breast tissue, for example, tamoxifen acts primarily as an oestrogen antagonist. It blocks the transcriptional activity of oestrogen receptors by directly binding to them, producing a nuclear complex that decreases DNA synthesis and inhibits oestrogen effects.</li></ul></li><li>Tamoxifen is licensed for:<ul><li>Treatment of oestrogen-receptor-positive breast cancer.</li><li>Treatment of anovulatory infertility. Patients being treated for infertility should be warned that there is a risk of multiple pregnancy (<em><em>rarely</em></em> more than twins).</li><li>Primary prevention of breast cancer in women at moderate or high risk.</li></ul></li><li>Tamoxifen is always initiated in secondary care by a specialist. However, treatment may be continued and monitored in primary care.</li><li>Tamoxifen is contraindicated in:<ul><li>Unless being used in the treatment of female infertility, effective contraception must be used during treatment and for 2 months after stopping. Pregnancy — women of childbearing potential should be advised not to become pregnant whilst taking tamoxifen or within two months of cessation of tamoxifen treatment. They should use barrier or other adequate non-hormonal contraceptive methods if sexually active. </li><li>Breastfeeding.</li><li>Treatment of infertility in women with a personal or family history of idiopathic venous thromboembolism (VTE) or a genetic predisposition to thromboembolism.</li><li>Primary prevention of breast cancer in women with a history of deep vein thrombosis or pulmonary embolism.</li></ul></li><li>Tamoxifen should be used with caution in:<ul><li>Treatment of breast cancer in women with a personal or family history of idiopathic VTE or a genetic predisposition to thromboembolism.</li><li>Acute porphyria.</li><li>Premenopausal women — tamoxifen has been associated with reduced bone density in premenopausal women. Premenopausal women taking tamoxifen should be advised regarding measures to maintain bone health.</li></ul></li><li>The most common adverse effects associated with tamoxifen are hot flushes (reported in about 50% of women), nausea, vaginal bleeding, vaginal discharge, fluid retention, fatigue, and skin rash. Uncommon but serious adverse effects include endometrial cancer or cancer flares, cerebrovascular events, thromboembolic events, and eye disorders.</li><li>Key drug interactions with tamoxifen include anastrozole, warfarin, cytochrome P450 2D6 inhibitors (such as paroxetine, fluoxetine, quinidine, cinacalcet, and bupropion), hormonal contraception, hormone replacement therapy (HRT), and tibolone.</li><li>Women taking tamoxifen should be advised:<ul><li>To continue taking tamoxifen unless told otherwise by their consultant.</li><li>That they should seek prompt medical attention if they experience any abnormal vaginal bleeding or discharge, or symptoms of thromboembolism (such as pain and swelling in the calf of one leg, and sudden breathlessness).</li><li>To seek medical attention if they experience any other adverse effects with tamoxifen. </li><li>On the need for effective contraception during treatment with tamoxifen and for 2 months after stopping treatment. They should discuss with their consultant if they are trying to conceive. </li><li>To discuss with their consultant if they are scheduled for an elective surgery. Tamoxifen may need to be stopped at least 6 weeks before elective surgery.</li><li>On the need for periodic monitoring whilst taking tamoxifen. This is usually done in secondary care and may include breast and gynaecological examination.</li></ul></li></ul><!-- end field 88227c79-471e-44f4-8daf-0522c2290da6 --><!-- end item 0845f642-9890-4944-91cd-c221e12362a5 -->","topic":{"id":"843d50d1-29e0-5a25-b29d-4d009d4ca56b","topicId":"3c8ceccf-c939-4885-bf43-dff38de8f940","topicName":"Tamoxifen - managing adverse effects","slug":"tamoxifen-managing-adverse-effects","aliases":[],"chapters":[{"id":"68b30489-1c21-5691-aa91-d98c85819055","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"3902ae23-4436-5f34-954f-61ee513623ad","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"9c316fc9-3054-50cd-8e92-91608fd623e3","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"822375d2-f573-54dc-9af4-4cafe8094b70","slug":"changes","fullItemName":"Changes"},{"id":"4fc88cec-4de4-5284-976a-8ff9c926937b","slug":"update","fullItemName":"Update"}]},{"id":"3254e7b2-0406-5c0f-bd0a-d382915875ec","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"853ae85c-163b-5ccf-a644-b072b18b9fca","slug":"goals","fullItemName":"Goals"},{"id":"c3b62b71-183a-5bee-bd03-125e3b658e3c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4bae49ff-a702-5f72-b2d0-f46009108792","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"dbdc028f-d934-59f6-91ca-bf671c6ed1bd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3b6ca9fb-1d57-5cbb-9532-96c1bff9189d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8ca455d2-3037-5131-bb24-2196750b0f52","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"204b504a-d22b-5a27-a20f-f08f20c3591b","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"69c80182-34aa-574b-8416-bc35ff6b2570","slug":"definition","fullItemName":"Definition"}]},{"id":"1f50f511-890e-545d-8d87-c607a1a4d1e2","slug":"management","fullItemName":"Management","subChapters":[{"id":"fc761c4a-bd2a-5463-96c8-861d67a66e30","slug":"tamoxifen-prescribing-information","fullItemName":"Scenario: Tamoxifen - prescribing information"}]},{"id":"f7ed77db-551a-5fd6-92d5-f93f53a97371","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"da6173b5-10a1-58a6-9931-e08d1f99d6c0","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"ae24edbd-49ce-530e-9e4b-4367a855974e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4fa9ad0b-2994-5c86-99d2-265267b32373","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bbed3b56-4479-5b7a-a72a-79307a374780","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ebc820e0-9d21-571c-b402-0ca097dbf174","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e2cc02a-ab60-597e-a108-ae6b27aafd5d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"41fcafe7-39c4-51a2-b67a-c091704fdf89","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"843d50d1-29e0-5a25-b29d-4d009d4ca56b","topicId":"3c8ceccf-c939-4885-bf43-dff38de8f940","topicName":"Tamoxifen - managing adverse effects","slug":"tamoxifen-managing-adverse-effects","aliases":[],"topicSummary":"Tamoxifen is an anti-oestrogen drug licensed for the treatment of breast cancer and anovulatory infertility.","lastRevised":"Last revised in November 2019","nextPlannedReviewBy":"2024-11-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2024-11","nextPlannedReviewByDisplay":"November 2024","specialities":[{"id":"45db1917-4d65-58d8-af3d-568321e486ed","name":"Drugs and devices","slug":"drugs-devices"},{"id":"0c813417-9691-5826-9371-c4bec6c53f06","name":"Women's health","slug":"womens-health"}],"chapters":[{"id":"68b30489-1c21-5691-aa91-d98c85819055","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"3902ae23-4436-5f34-954f-61ee513623ad","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"9c316fc9-3054-50cd-8e92-91608fd623e3","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"822375d2-f573-54dc-9af4-4cafe8094b70","slug":"changes","fullItemName":"Changes"},{"id":"4fc88cec-4de4-5284-976a-8ff9c926937b","slug":"update","fullItemName":"Update"}]},{"id":"3254e7b2-0406-5c0f-bd0a-d382915875ec","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"853ae85c-163b-5ccf-a644-b072b18b9fca","slug":"goals","fullItemName":"Goals"},{"id":"c3b62b71-183a-5bee-bd03-125e3b658e3c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4bae49ff-a702-5f72-b2d0-f46009108792","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"dbdc028f-d934-59f6-91ca-bf671c6ed1bd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3b6ca9fb-1d57-5cbb-9532-96c1bff9189d","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8ca455d2-3037-5131-bb24-2196750b0f52","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"204b504a-d22b-5a27-a20f-f08f20c3591b","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"69c80182-34aa-574b-8416-bc35ff6b2570","slug":"definition","fullItemName":"Definition"}]},{"id":"1f50f511-890e-545d-8d87-c607a1a4d1e2","slug":"management","fullItemName":"Management","subChapters":[{"id":"fc761c4a-bd2a-5463-96c8-861d67a66e30","slug":"tamoxifen-prescribing-information","fullItemName":"Scenario: Tamoxifen - prescribing information"}]},{"id":"f7ed77db-551a-5fd6-92d5-f93f53a97371","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"da6173b5-10a1-58a6-9931-e08d1f99d6c0","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"ae24edbd-49ce-530e-9e4b-4367a855974e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4fa9ad0b-2994-5c86-99d2-265267b32373","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bbed3b56-4479-5b7a-a72a-79307a374780","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ebc820e0-9d21-571c-b402-0ca097dbf174","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e2cc02a-ab60-597e-a108-ae6b27aafd5d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"41fcafe7-39c4-51a2-b67a-c091704fdf89","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"843d50d1-29e0-5a25-b29d-4d009d4ca56b"}},"staticQueryHashes":["3666801979"]}